IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity

Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. The firm strongly believes it will benefit as market fundamentals improve. For the year, the portfolio declined by 1.4%, underperforming the MSCI ACWI's 22.9% return. Momentum has dominated equity markets, with performance driven more by narratives than fundamentals. The firm admits the risks of being different but will remain contrarian and strategic, adapting more quickly to changing facts. In addition, please check the Portfolio’s top five holdings to know its best picks in 2025.

In its fourth-quarter 2025 investor letter, Broyhill Asset Management highlighted IQVIA Holdings Inc. (NYSE:IQV) as one of its top contributors. IQVIA Holdings Inc. (NYSE:IQV) is a leading provider of clinical research services, technology solutions, and healthcare intelligence to the life sciences and healthcare industries. On February 25, 2026, IQVIA Holdings Inc. (NYSE:IQV) stock closed at $161.91 per share. One-month return of IQVIA Holdings Inc. (NYSE:IQV) was -31.28%, and its shares lost 13.18% over the past 52 weeks. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $27.573 billion.

Broyhill Asset Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its fourth quarter 2025 investor letter:

"Our largest contributors were Philip Morris, Dollar Tree, and IQVIA Holdings Inc. (NYSE:IQV). Winners shared a common thread: durable businesses with identifiable catalysts that the market had mispriced. IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company’s role as a mission-critical infrastructure to drug development remains unchallenged. The first leg of the industry’s recent rally was sparked by stabilization, rewarding patience through a prolonged industry downturn. We expect the next leg to gain steam as the recovery accelerates."

IQVIA Holdings Inc. (NYSE:IQV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 69 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the fourth quarter, up from 61 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered IQVIA Holdings Inc. (NYSE:IQV) and shared a list of best life sciences stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.